Analysis of 14,392 whole genomes reveals 3.5% of Qataris carry medically actionable variants
-
Published:2024-07-17
Issue:
Volume:
Page:
-
ISSN:1018-4813
-
Container-title:European Journal of Human Genetics
-
language:en
-
Short-container-title:Eur J Hum Genet
Author:
Elfatih Amal, Saad ChadiORCID, Ismail Said, Al-Muftah Wadha, Badji Radja, Darwish Dima, Fadl Tasnim, Yasin Heba, Ennaifar Maryem, Abdel-latif Rania, Alkuwari Fatima, Alvi Muhammad, Sarraj Yasser Al, Althani Asmaa, Fthenou Eleni, Qafoud Fatima, Alkhayat Eiman, Afifi Nahla, Tomei Sara, Liu Wei, Lorenz Stephan, Syed Najeeb, Almabrazi Hakeem, Vempalli Fazulur Rehaman, Temanni Ramzi, Saqri Tariq Abu, Khatib Mohammed husen, Hamza Mehshad, Zaid Tariq Abu, El Khouly Ahmed, Pathare Tushar, Poolat Shafeeq, Al-Ali Rashid, Albagha Omar M. E., Al-Khodor Souhaila, Alshafai Mashael, Badii Ramin, Chouchane Lotfi, Estivill Xavier, Fakhro Khalid, Mbarek Hamdi, Mokrab Younes, Puthen Jithesh V., Suhre Karsten, Tatari Zohreh, Mifsud BorbalaORCID, Mbarek HamdiORCID, , , , , , ,
Abstract
AbstractArabic populations are underrepresented in large genome projects; therefore, the frequency of clinically actionable variants among Arabs is largely unknown. Here, we investigated genetic variation in 14,392 whole genomes from the Qatar Genome Program (QGP) across the list of 78 actionable genes (v3.1) determined by the American College of Medical Genetics and Genomics (ACMG). Variants were categorized into one of the following groups: (1) Pathogenic (P), (2) Likely pathogenic (LP), and (3) Rare variants of uncertain significance with evidence of pathogenicity. For the classification, we used variant databases, effect predictors, and the disease-relevant phenotypes available for the cohort. Data on cardiovascular disease, cancer, and hypercholesterolemia allowed us to assess the disease-relevant phenotype association of rare missense variants. We identified 248 distinct variants in 50 ACMG genes that fulfilled our criteria to be included in one of the three groups affecting 1036 genotype-positive participants of the QGP cohort. The most frequent variants were in TTN, followed by RYR1 and ATP7B. The prevalence of reportable secondary findings was 3.5%. A further 46 heterozygous variants in six genes with an autosomal recessive mode of inheritance were detected in 200 individuals, accounting for an additional 1.4%. Altogether, they affect 5% of the population. Due to the high consanguinity rate in the QGP cohort (28% in spouses and 60% in parents), P and LP variants both in genes with dominant and recessive inheritance are important for developing better treatment options and preventive strategies in Qatar and the Arabic population of the Middle East.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Roberts MC, Fohner AE, Landry L, Olstad DL, Smit AK, Turbitt E, et al. Advancing precision public health using human genomics: examples from the field and future research opportunities. Genome Med [Internet]. 2021;13:1–10. https://genomemedicine.biomedcentral.com/articles/10.1186/s13073-021-00911-0. 2. Thauvin-Robinet C, Thevenon J, Nambot S, Delanne J, Kuentz P, Bruel AL, et al. Secondary actionable findings identified by exome sequencing: expected impact on the organisation of care from the study of 700 consecutive tests. Eur J Hum Genet. 2019;27:1197–214. https://www.nature.com/articles/s41431-019-0384-7. 3. Elfatih A, Mohammed I, Abdelrahman D, Mifsud B. Frequency and management of medically actionable incidental findings from genome and exome sequencing data: a systematic review. https://doi.org/10.1152/physiolgenomics000252021 [Internet]. 2021 Sep 1 [cited 2021 Oct 10];53:373–84. 4. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med [Internet]. 2017;19:249–55. https://www.nature.com/articles/gim2016190. 5. Miller DT, Lee K, Chung WK, Gordon AS, Herman GE, Klein TE, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med [Internet]. 2021;23:1391–8. https://doi.org/10.1038/s41436-021-01171-4.
|
|